Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...4243444546474849505152...401402»
  • ||||||||||  Review, Journal:  Physical exercise as a modulator of the purinergic system in the control of sarcopenia in individuals with chronic kidney disease on hemodialysis. (Pubmed Central) -  Jun 18, 2024   
    Furthermore, it appears that there is a correlation between the practice of repeated physical exercise with the clinical improvement and in the quality of life of these patients, presenting a decrease in the levels of C-reactive protein (CRP), NTPDase, and the pro-inflammatory cytokine IL-6, such as increases in IL-10 resulting from modulation of the purinergic system. In this way, the present article seeks to evaluate the effect of physical exercise as a modulator of the purinergic system in the control of sarcopenia in patients with CKD on hemodialysis, in order to trace a relationship that can bring benefits both for biological markers and for quality of life of these patients.
  • ||||||||||  Clinical, Observational data, Retrospective data, Review, Journal:  Osteosarcopenia increases the risk of mortality: a systematic review and meta-analysis of prospective observational studies. (Pubmed Central) -  Jun 18, 2024   
    Sarcopenia was significantly associated with OS (HR:1.62; 95% CI: 1.43-1.83; P?<?0.001, I2 Osteosarcopenia was significantly linked with an increased risk of mortality in older people, indicating the need to consider the presence of osteoporosis in patients with sarcopenia, and vice versa, since the combination of these two conditions typical of older people may lead to further complications, such as mortality.
  • ||||||||||  Piqray (alpelisib) / Novartis
    Retrospective data, Journal:  Body composition measures as a determinant of Alpelisib related toxicity. (Pubmed Central) -  Jun 17, 2024   
    Body composition measures, specifically SMD and VAT may provide an opportunity to identify patients at higher risk for severe alpelisib related hyperglycemia, and cutaneous toxicity. These findings suggest the potential use of body composition assessment to caution toxicity risk, allowing for personalized therapeutic observation and intervention.
  • ||||||||||  Journal:  Malnutrition, sarcopenia and cachexia: exploring prevalence, overlap, and perceptions in older adults with cancer. (Pubmed Central) -  Jun 17, 2024   
    These findings suggest the potential use of body composition assessment to caution toxicity risk, allowing for personalized therapeutic observation and intervention. Perceptions, identification, and management of these conditions needs to improve, and their importance recognised by clinicians and patients so those truly 'at risk' are identified whilst conditions are more remediable to interventions.
  • ||||||||||  Journal:  Long-term inequalities in health among older Mexican adults: An outcome-wide analysis. (Pubmed Central) -  Jun 17, 2024   
    Health inequalities in old age are one of the greatest challenges facing health systems globally. Actions like universal coverage of health services for older people and the empowerment of individuals and their communities to have control over their lives and circumstances must be guaranteed.
  • ||||||||||  Adlumiz (anamorelin) / Helsinn
    Journal:  Efficacy of Anamorelin for the Treatment of Cancer Cachexia and Factors Associated with Weight Gain (Pubmed Central) -  Jun 17, 2024   
    The factors that contributed to weight gain in patients before starting anamorelin were as follows: the patients' disease stage had not progressed to refractory cachexia based on the cancer cachexia classification of the European Palliative Care Research Collaborative; the patients had received fewer lines of anticancer treatment at the start of oral administration of anamorelin; and the patients had not met all the criteria for starting treatment with anamorelin, namely, C-reactive protein level >0.5 mg/dL, hemoglobin level <12 g/dL, and albumin level <3.2 g/dL. These results suggest that early administration of anamorelin hydrochloride tablets may increase the response rate when cancer cachexia is diagnosed.
  • ||||||||||  Review, Journal:  Use of electrical bioimpedance in the assessment of sarcopenia in the older aldults: A scoping review. (Pubmed Central) -  Jun 15, 2024   
    The data from this research show that ASMM and phase angle are the main variables related to sarcopenia screening in community-dwelling older adults. Whereas total extracellular water/body water is still considered a confounding variable in the screening of sarcopenia in the elderly, but it can be considered useful regarding the health conditions of the elderly in the community.
  • ||||||||||  Journal:  Adipocyte secreted NRG4 ameliorates age-associated metabolic dysfunction. (Pubmed Central) -  Jun 15, 2024   
    In addition, rNRG4 treatment improves age-associated hepatic steatosis and sarcopenia, accompanied with altered gene signatures. Together, these results indicate that NRG4 plays a key role in the aging process and is a therapeutic target for the treatment of age-associated metabolic dysfunction.
  • ||||||||||  Review, Journal:  Unlocking longevity with GLP-1: A key to turn back the clock? (Pubmed Central) -  Jun 15, 2024   
    Determining optimal dosages, establishing long-term safety profiles, and investigating potential adverse effects require comprehensive clinical investigations before we can confidently translate these findings to humans. This article emphasises the wide applicability of GLP-1.
  • ||||||||||  Journal:  Sarcopenic Obesity and Outcomes for Patients With Cancer. (Pubmed Central) -  Jun 14, 2024   
    Weak HGS, 1 of the diagnostic conditions, was the only component of SO associated with OS. The ESPEN-EASO algorithm appears to be an applicable tool to identify cancer-associated SO, which represents a major clinical complication and factor associated with risk for poor outcomes in these patients.
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Sarcopenia and Its Associated Factors Among Hip Fractures Patients (clinicaltrials.gov) -  Jun 14, 2024   
    P=N/A,  N=135, Completed, 
    No abstract available Not yet recruiting --> Completed | Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Aug 2023
  • ||||||||||  Enrollment open:  Blend-D2O: Plant Protein Blend and Milk Protein Supplements in Older Individuals (clinicaltrials.gov) -  Jun 13, 2024   
    P=N/A,  N=42, Recruiting, 
    Our findings provide an insight for therapy against sarcopenia through alleviating oxidative damage-induced dysfunctional mitochondria by targeting peroxiredoxin 5, which may contribute an insight for healthy aging. Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  Interrelationship of Sarcopenia and Cardiovascular Diseases: A Review of Potential Mechanisms and Management. (Pubmed Central) -  Jun 12, 2024   
    In this review, we discuss how processes such as inflammation, oxidative stress, endothelial dysfunction, neural and hormonal modifications, as well as other metabolic disturbances influence sarcopenia as well as its association with cardiovascular diseases. Moreover, this review provides an overview of both non-pharmacological and pharmacological management for patients with sarcopenia and cardiovascular diseases, with a focus on the potential role of cardiovascular drugs to mitigate sarcopenia.
  • ||||||||||  Review, Journal:  The Roles of Non-Pharmacologic and Emerging Pharmacologic Management of Non-alcoholic Fatty Liver Disease and Sarcopenia: A Narrative Review. (Pubmed Central) -  Jun 12, 2024   
    This narrative review will examine the pathophysiologic overlaps that can explain the links between NAFLD and sarcopenia. Furthermore, this review will explore the emerging roles of nonpharmacologic (e.g., weight reduction, diet, alcohol, and smoking cessation, and physical activity) and pharmacologic management (e.g., roles of ?-hydroxy-?-methylbutyrate, branched-chain amino acid supplements, and testosterone therapy) to improve care, intervention sustainability, and acceptability for patients with sarcopenia-associated NAFLD.
  • ||||||||||  Journal:  The time window for pre-emptive transjugular intrahepatic portosystemic shunt could be extended to 5 days. (Pubmed Central) -  Jun 12, 2024   
    Furthermore, this review will explore the emerging roles of nonpharmacologic (e.g., weight reduction, diet, alcohol, and smoking cessation, and physical activity) and pharmacologic management (e.g., roles of ?-hydroxy-?-methylbutyrate, branched-chain amino acid supplements, and testosterone therapy) to improve care, intervention sustainability, and acceptability for patients with sarcopenia-associated NAFLD. In the total cohort, sarcopenia was identified as an independent risk factor for mortality (HR